Synthesis of galmic: a nonpeptide galanin receptor agonist.

  title={Synthesis of galmic: a nonpeptide galanin receptor agonist.},
  author={Susana Conde Ceide and Laurent Trembleau and Gebhard Haberhauer and Laszlo P. Somogyi and Xiaoying Lu and Tam{\'a}s B{\'a}rtfai and Julius Rebek},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  volume={101 48},
  • S. C. Ceide, L. Trembleau, J. Rebek
  • Published 30 November 2004
  • Chemistry, Biology
  • Proceedings of the National Academy of Sciences of the United States of America
Galanin is a neuropeptide with a wide variety of biological functions. Few nonpeptide ligands, capable of activating galanin receptors, are available today. Based on known pharmacophores of galanin and the tripeptidomimetic galnon, a combinatorial library was formulated, synthesized, and screened against the galanin receptor. An active compound, galmic, was identified and tested in vitro and in vivo for its affinity and efficacy at galanin receptors. The present work describes the total… 

Figures from this paper

Galanin Receptors and Ligands
This review aims to summarize the current data of the importance of the galanin receptor subtypes and receptor subtype specific agonists and antagonists and their involvement in different biological and pathological functions.
Galanin receptors as a potential target for neurological disease
The importance of the galanin neurochemical system as a potential target for drug development is highlighted with recent advances and novel approaches in migrating the directions of subtype-selective ligand development and chemical modifications of the peptide backbone highlighted.
Galanin receptor ligands
A novel design strategy for galanin receptor ligands is provided and the understanding of ligand interactions with the GalR3 is increased, holding promises to future delineation of the Galaninergic system as a therapeutic target.
Theoretical investigation of selective ligand binding mode of galanin receptors.
This study provides rationale for further in silico virtual screening of small molecules for the development of selective ligands against Galanin receptor subtypes and subtypes ligands binding selectivity.
Preclinical evaluation of intravenous NAX 810‐2, a novel GalR2‐preferring analog, for anticonvulsant efficacy and pharmacokinetics
NAX 810‐2, a galanin receptor subtype 2 (GalR2)‐preferring galan in analog, possesses 15‐fold greater affinity for GalR2 over GalR1 and protects against seizures in the mouse 6 Hz, corneal kindling, and Frings audiogenic seizure models.
Positive allosteric modulators to peptide GPCRs: a promising class of drugs
This review, which focuses on the general principles of finding PAMs of peptide receptors in the 21st century, describes the workflow and some of its resulting compounds such as P AMs of galanin receptor 2 that act as potent anticonvulsant agents.
Preclinical Analgesic and Safety Evaluation of the GalR2-preferring Analog, NAX 810-2
Evaluated galanin receptor type 2-preferring analog NAX 810-2 possesses a favorable pre-clinical profile as a novel and first-in-class analgesic and any potential for insulin inhibition, growth hormone stimulation, and cognitive impairment is determined.
Anticonvulsant neuropeptides as drug leads for neurological diseases.
Two main objectives of this review are to provide an overview of structural and pharmacological properties for selected anticonvulsant neuropeptides and their analogs and to encourage broader efforts to convert these endogenous natural products into drug leads for pain, epilepsy and other neurological diseases.


Galanin receptor subtypes and ligand binding
A review highlights the recent reports on the binding affinities of GalR in CNS and transfected cell lines to provide insights into the role of galanin both at normal and pathophysiological conditions, and in the development of compounds with therapeutical values.
Anticonvulsant activity of a nonpeptide galanin receptor agonist
  • K. Saar, A. Mazarati, Ü. Langel
  • Biology, Chemistry
    Proceedings of the National Academy of Sciences of the United States of America
  • 2002
Findings introduce a systemically active nonpeptide galanin agonist anticonvulsant through this receptor subtype.
Galanin receptor subtypes.
Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests.
  • T. Bártfai, X. Lu, J. Rebek
  • Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 2004
The present work uses the tripeptidomimetic galnon and displays its presumed pharmacophores on a rigid molecular scaffold and provides an example of a systemically active compound based on a scaffold that mimics protein surfaces.
The role of galanin in feeding behavior
The mechanisms by which exogenously administered Galanin may stimulate ingestion are summarized, pharmacological and genetic investigations of the role of endogenous galanin on feeding and body weight are discussed, and the therapeutic potential of non-peptide galanIn receptor antagonists for the treatment of appetite disorders are speculated on.
Linear and cyclic N-terminal galanin fragments and analogs as ligands at the hypothalamic galanin receptor.
L-Ala substitutions show that amino acid residues Gly1, Trp2, Asn5, Tyr9, and Gly12 are important for the high affinity binding of galanin (1-16) and the importance of the free N-terminal Gly.
Galanin and spinal nociceptive mechanisms: recent advances and therapeutic implications
Peripheral nerve injury and inflammation, conditions associated with chronic pain, upregulate the synthesis of galanin in sensory neurons and spinal cord neurons, respectively, raising the possibility that modulation of the activity of the Galanin system may produce antinociception.